SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01705639

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?

The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated. The following will be done at 0 and 3 months: - OGTT - questionnaires about sleep and activity - Actigraph - Anthropometry - Blood pressure

NCT01705639 Diabetes Glucose Tolerance

1 Interventions

Name: Melatonin

Description: All subjects receive the same dose of melatonin
Type: Drug
Group Labels: 1

Melatonin

Primary Outcomes

Description: Glucose tolerance is measured in OGTT: 0,30,60,90 and 120 minute values of glucose and insulin.

Measure: Glucose tolerance

Time: 3 months

Secondary Outcomes

Description: monitoring of sleep with questionnaires and activity monitoring

Measure: sleep

Time: 3 months

Description: Activity and sleep of the subjects is recorded with Actigraph at 0 and 3 months

Measure: Activity

Time: 3 months
Purpose: Basic Science

Allocation: N/A

Single Group Assignment

There is one SNP

SNPs

1 rs10830963

Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?. Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants of the melatonin receptor 1B gene will be evaluated.


HPO Nodes